Novo Nordisk challenges Pfizer with a $6.5 billion bid for Metsera, offering a higher price and potential upside, but Pfizer denounces the proposal as 'reckless and unprecedented'.
Novo Nordisk challenges Pfizer with a $6.5 billion bid for Metsera, offering a higher price and potential upside, but Pfizer denounces the proposal as 'reckless and unprecedented'.